Cytek Biosciences Inc (CTKB)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -12,148 | -13,933 | -5,851 | -2,165 | 2,484 | -2,399 | -2,605 | 767 | |||
| Total stockholders’ equity | US$ in thousands | 393,064 | 415,524 | 424,179 | 423,460 | 425,546 | 416,509 | 411,129 | 407,442 | 405,385 | 403,195 | -10,985 |
| ROE | -3.09% | -3.35% | -1.38% | -0.51% | 0.58% | -0.58% | -0.63% | 0.19% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-12,148K ÷ $393,064K
= -3.09%
Cytek Biosciences Inc has experienced negative ROE for the past several quarters, indicating that the company is not generating significant returns for its shareholders compared to the equity invested. The downward trend in ROE from -3.09% in December 2023 to -0.51% in March 2023 suggests a declining profitability and efficiency in utilizing shareholder equity. The positive ROE of 0.58% in December 2022 was a brief improvement, but the subsequent quarters show a return to negative territory.
Overall, Cytek Biosciences Inc's ROE performance indicates a concerning pattern of underperformance and inefficiency in generating returns for shareholders. Further analysis of the company's financial management and operational strategies may be needed to address and improve its ROE in the future.
Peer comparison
Dec 31, 2023